MR-guided focused ultrasound: Enhancement of intratumoral uptake of [ 3H]-docetaxel in vivo

Lili Chen, Zhaomei Mu, Paul Hachem, C. M. Ma, Annie Wallentine, Alan Pollack

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The purpose of this study is to quantify the enhancement of [ 3H]-docetaxel in implanted prostate tumors treated with MR-guided pulsed focused ultrasound (MRgFUS). Human prostate cancer, LNCaP cells in 25 μl, were implanted into the prostates of male nude mice. The tumor growth was directly monitored on MRI. When the tumor reached a designated size, MRgFUS treatment was performed using a focused ultrasound treatment system (InSightec ExAblate 2000) with a 1.5 T GEMR scanner. The tumor-bearing animals were randomly divided into three groups: group 1, MRgFUS treatment + [ 3H]-docetaxel; group 2, [3H]-docetaxel only and group 3, as a control. Animals in group 1 were treated with MRgFUS non-invasively. Immediately after the treatment, the animals received a single dose of tail vein injection of docetaxel at 15 mg kg-1 mixed with [3H]-docetaxel at 50 uCi kg-1 in a total volume of 150 μl. Animals in group 2 were treated the same as in group one, however without MRgFUS treatment. Animals in group 3 were treated as a control. Animals were sacrificed 30 min after i.v. injections regardless of whether or not they received focused ultrasound. Tumors were removed and processed. The radioactivity of [3H]-docetaxel in the tumor tissue was quantitatively measured by a liquid scintillation counter. Our study showed that all animals tolerated the MRgFUS treatment well. Our data showed increased 3H-docetaxel concentration in the tumor in the MRgFUS-treated group (1079 ± 132 cmp/75 mg) versus those without MRgFUS treatment (524 ± 201 cmp/75 mg) with P = 0.037.

Original languageEnglish
Pages (from-to)7399-7410
Number of pages12
JournalPhysics in Medicine and Biology
Volume55
Issue number24
DOIs
StatePublished - Dec 21 2010

Fingerprint

docetaxel
Neoplasms
Therapeutics
Prostate
Scintillation Counting
Injections
Ultrasonic Waves
Nude Mice
Radioactivity
Tail

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

MR-guided focused ultrasound : Enhancement of intratumoral uptake of [ 3H]-docetaxel in vivo. / Chen, Lili; Mu, Zhaomei; Hachem, Paul; Ma, C. M.; Wallentine, Annie; Pollack, Alan.

In: Physics in Medicine and Biology, Vol. 55, No. 24, 21.12.2010, p. 7399-7410.

Research output: Contribution to journalArticle

Chen, Lili ; Mu, Zhaomei ; Hachem, Paul ; Ma, C. M. ; Wallentine, Annie ; Pollack, Alan. / MR-guided focused ultrasound : Enhancement of intratumoral uptake of [ 3H]-docetaxel in vivo. In: Physics in Medicine and Biology. 2010 ; Vol. 55, No. 24. pp. 7399-7410.
@article{379ed670f4794043b055e7d469cba2f2,
title = "MR-guided focused ultrasound: Enhancement of intratumoral uptake of [ 3H]-docetaxel in vivo",
abstract = "The purpose of this study is to quantify the enhancement of [ 3H]-docetaxel in implanted prostate tumors treated with MR-guided pulsed focused ultrasound (MRgFUS). Human prostate cancer, LNCaP cells in 25 μl, were implanted into the prostates of male nude mice. The tumor growth was directly monitored on MRI. When the tumor reached a designated size, MRgFUS treatment was performed using a focused ultrasound treatment system (InSightec ExAblate 2000) with a 1.5 T GEMR scanner. The tumor-bearing animals were randomly divided into three groups: group 1, MRgFUS treatment + [ 3H]-docetaxel; group 2, [3H]-docetaxel only and group 3, as a control. Animals in group 1 were treated with MRgFUS non-invasively. Immediately after the treatment, the animals received a single dose of tail vein injection of docetaxel at 15 mg kg-1 mixed with [3H]-docetaxel at 50 uCi kg-1 in a total volume of 150 μl. Animals in group 2 were treated the same as in group one, however without MRgFUS treatment. Animals in group 3 were treated as a control. Animals were sacrificed 30 min after i.v. injections regardless of whether or not they received focused ultrasound. Tumors were removed and processed. The radioactivity of [3H]-docetaxel in the tumor tissue was quantitatively measured by a liquid scintillation counter. Our study showed that all animals tolerated the MRgFUS treatment well. Our data showed increased 3H-docetaxel concentration in the tumor in the MRgFUS-treated group (1079 ± 132 cmp/75 mg) versus those without MRgFUS treatment (524 ± 201 cmp/75 mg) with P = 0.037.",
author = "Lili Chen and Zhaomei Mu and Paul Hachem and Ma, {C. M.} and Annie Wallentine and Alan Pollack",
year = "2010",
month = "12",
day = "21",
doi = "10.1088/0031-9155/55/24/001",
language = "English",
volume = "55",
pages = "7399--7410",
journal = "Physics in Medicine and Biology",
issn = "0031-9155",
publisher = "IOP Publishing Ltd.",
number = "24",

}

TY - JOUR

T1 - MR-guided focused ultrasound

T2 - Enhancement of intratumoral uptake of [ 3H]-docetaxel in vivo

AU - Chen, Lili

AU - Mu, Zhaomei

AU - Hachem, Paul

AU - Ma, C. M.

AU - Wallentine, Annie

AU - Pollack, Alan

PY - 2010/12/21

Y1 - 2010/12/21

N2 - The purpose of this study is to quantify the enhancement of [ 3H]-docetaxel in implanted prostate tumors treated with MR-guided pulsed focused ultrasound (MRgFUS). Human prostate cancer, LNCaP cells in 25 μl, were implanted into the prostates of male nude mice. The tumor growth was directly monitored on MRI. When the tumor reached a designated size, MRgFUS treatment was performed using a focused ultrasound treatment system (InSightec ExAblate 2000) with a 1.5 T GEMR scanner. The tumor-bearing animals were randomly divided into three groups: group 1, MRgFUS treatment + [ 3H]-docetaxel; group 2, [3H]-docetaxel only and group 3, as a control. Animals in group 1 were treated with MRgFUS non-invasively. Immediately after the treatment, the animals received a single dose of tail vein injection of docetaxel at 15 mg kg-1 mixed with [3H]-docetaxel at 50 uCi kg-1 in a total volume of 150 μl. Animals in group 2 were treated the same as in group one, however without MRgFUS treatment. Animals in group 3 were treated as a control. Animals were sacrificed 30 min after i.v. injections regardless of whether or not they received focused ultrasound. Tumors were removed and processed. The radioactivity of [3H]-docetaxel in the tumor tissue was quantitatively measured by a liquid scintillation counter. Our study showed that all animals tolerated the MRgFUS treatment well. Our data showed increased 3H-docetaxel concentration in the tumor in the MRgFUS-treated group (1079 ± 132 cmp/75 mg) versus those without MRgFUS treatment (524 ± 201 cmp/75 mg) with P = 0.037.

AB - The purpose of this study is to quantify the enhancement of [ 3H]-docetaxel in implanted prostate tumors treated with MR-guided pulsed focused ultrasound (MRgFUS). Human prostate cancer, LNCaP cells in 25 μl, were implanted into the prostates of male nude mice. The tumor growth was directly monitored on MRI. When the tumor reached a designated size, MRgFUS treatment was performed using a focused ultrasound treatment system (InSightec ExAblate 2000) with a 1.5 T GEMR scanner. The tumor-bearing animals were randomly divided into three groups: group 1, MRgFUS treatment + [ 3H]-docetaxel; group 2, [3H]-docetaxel only and group 3, as a control. Animals in group 1 were treated with MRgFUS non-invasively. Immediately after the treatment, the animals received a single dose of tail vein injection of docetaxel at 15 mg kg-1 mixed with [3H]-docetaxel at 50 uCi kg-1 in a total volume of 150 μl. Animals in group 2 were treated the same as in group one, however without MRgFUS treatment. Animals in group 3 were treated as a control. Animals were sacrificed 30 min after i.v. injections regardless of whether or not they received focused ultrasound. Tumors were removed and processed. The radioactivity of [3H]-docetaxel in the tumor tissue was quantitatively measured by a liquid scintillation counter. Our study showed that all animals tolerated the MRgFUS treatment well. Our data showed increased 3H-docetaxel concentration in the tumor in the MRgFUS-treated group (1079 ± 132 cmp/75 mg) versus those without MRgFUS treatment (524 ± 201 cmp/75 mg) with P = 0.037.

UR - http://www.scopus.com/inward/record.url?scp=78650053471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650053471&partnerID=8YFLogxK

U2 - 10.1088/0031-9155/55/24/001

DO - 10.1088/0031-9155/55/24/001

M3 - Article

C2 - 21098923

AN - SCOPUS:78650053471

VL - 55

SP - 7399

EP - 7410

JO - Physics in Medicine and Biology

JF - Physics in Medicine and Biology

SN - 0031-9155

IS - 24

ER -